N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl
申请人:Pfizer Inc.
公开号:US05656634A1
公开(公告)日:1997-08-12
Compounds of the formula ##STR1## the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined below, and novel carboxylic acid and acid halide intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.
New N-heteroarylamide derivatives as inhibitors of acyl coenzyme A: cholestrol acyl transferase
申请人:PFIZER INC.
公开号:EP0609960A1
公开(公告)日:1994-08-10
Compounds of the formula
the pharmaceutically acceptable salts thereof, wherein Q is a substituted pyridine or pyrimidine group and R¹ incorporates a hydrocarbon group of from 4 to 16 carbon atoms, are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.